Loading…
Cartesian Therapeutics, Inc. is projected to rise to $9.50 by 2027, a +1% move from its current price of $9.39. RNAC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $8.92 | $9.39 | $9.87 | 0.00% |
| Jul 14 | $8.74 | $9.39 | $10.08 | +0.01% |
| Jul 15 | $8.60 | $9.39 | $10.25 | +0.01% |
| Jul 16 | $8.48 | $9.39 | $10.39 | +0.02% |
| Jul 17 | $8.38 | $9.39 | $10.51 | +0.02% |
| Jul 18 | $8.29 | $9.39 | $10.63 | +0.02% |
| Jul 19 | $8.21 | $9.39 | $10.73 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.21 | $9.39 | $10.73 | +0.03% |
| Week 2 | $7.77 | $9.39 | $11.35 | +0.05% |
| Week 3 | $7.45 | $9.39 | $11.85 | +0.08% |
| Week 4 | $7.19 | $9.40 | $12.28 | +0.11% |
| Week 5 | $6.96 | $9.40 | $12.68 | +0.13% |
| Week 6 | $6.77 | $9.40 | $13.05 | +0.16% |
| Week 7 | $6.60 | $9.40 | $13.40 | +0.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company that provides mRNA cell therapies for the treatment of autoimmune diseases. Its lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy directed against BCMA, in Phase 2b clinical trials for autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, with rare pediatric disease designation for juvenile dermatomyositis.
The company is also developing Descartes-15, which is in Phase 1 trials, an autologous BCMA-directed mRNA CAR-T to treat patients with multiple myeloma. Cartesian Therapeutics is headquartered in Frederick, Maryland.
The current price for Cartesian Therapeutics, Inc. (RNAC) is $9.67. Its market capitalization is $284.12M and it is currently ranked 3568.
A major floor 58.7% below — a decisive break under it would weaken the trend.
The nearest floor, 37.8% below — buyers have tended to step in here.
The nearest ceiling, 12.8% above — a clean break opens room to run.
A major ceiling 42.6% above — clearing it would confirm fresh momentum.
Key RNAC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNAC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.95 | Sell | $9.83 | Sell |
| MA 10 | $10.00 | Sell | $9.83 | Sell |
| MA 20 | $9.67 | Sell | $9.43 | Sell |
| MA 50 | $8.13 | Buy | $8.48 | Buy |
| MA 100 | $7.50 | Buy | $7.99 | Buy |
| MA 200 | $7.70 | Buy | $8.49 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.92 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -29.59 | Neutral |
| Williams %R (14) | -68.07 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -7.07 | Sell |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 31.93 | Neutral |
| TRIX (15) | 1.27 | Buy |
| Awesome (5,34) | 1.51 | Buy |
| Ultimate (7,14,28) | 37.96 | Neutral |
| Momentum (10) | 0.53 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 9.75 | Sell |
| ADX (14) | 19.39 | Neutral |
| ATR (14) | 0.43 | Info |
The 30-day technical picture shows a BULLISH sentiment with RSI 14 at 50. The near-term trend is supported by the moving average alignment, with SMA50 at $8.07 and SMA200 at $7.71. The stock trades within a 30-day range of $6.86 to $13.63, with a defined support at $5.84 and a resistance at $10.59. Annualized volatility is 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.84 | $9.39 | $12.21 | 0% | Neutral | |
| $6.96 | $9.50 | $13.99 | +1% | Neutral | |
| $6.67 | $9.64 | $15.09 | +3% | Neutral | |
| $7.01 | $10.63 | $17.45 | +13% | Neutral | |
| $8.31 | $13.17 | $22.46 | +40% | Bullish | |
| $9.69 | $15.99 | $28.20 | +70% | Bullish | |
| $10.82 | $18.58 | $33.75 | +98% | Bullish | |
| $10.49 | $18.68 | $34.85 | +99% | Bullish | |
| $9.99 | $18.46 | $35.29 | +97% | Bullish | |
| $9.50 | $18.18 | $35.53 | +94% | Bullish | |
| $15.16 | $33.68 | $72.14 | +259% | Bullish | |
| $20.43 | $45.40 | $104.42 | +384% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.84 | $9.39 | $11.93 | +0.00% |
| August 2026 | $8.10 | $9.79 | $12.30 | +4.28% |
| September 2026 | $7.69 | $9.42 | $12.07 | -3.76% |
| October 2026 | $7.75 | $9.60 | $12.51 | +1.89% |
| November 2026 | $7.79 | $9.75 | $12.88 | +1.60% |
| December 2026 | $7.23 | $9.12 | $12.21 | -6.43% |
Click any year to see its month-by-month RNAC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RNAC to range from $5.84 to $12.21 through 2026. The $9.39 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The RNAC price prediction for 2027 points to an average of $9.50 (low $6.96, high $13.99) — a potential gain of +1% on today's $9.39. Price action looks broadly range-bound.
In 2028, RNAC is projected to trade between $6.67 and $15.09, averaging $9.64 — a potential gain of +3% from today's $9.39. That is up +1% on the projected 2027 average. A consolidation phase looks the most probable path here.
Cartesian Therapeutics, Inc.'s 2029 outlook centres on $10.63, within a $7.01 to $17.45 range. That is up +10% on the projected 2028 average. That marks a +13% change versus current levels. Price action looks broadly range-bound.
By 2030, RNAC could reach as high as $22.46, with a base case around $13.17 and support toward $8.31 — roughly +40% from $9.39. Buyers look set to stay in control over this stretch.
Expect RNAC to range from $9.69 to $28.20 through 2031. The $15.99 average target implies a +70% move from current prices. That is up +21% on the projected 2030 average. Momentum favours further upside here.
The RNAC price prediction for 2032 points to an average of $18.58 (low $10.82, high $33.75) — a potential gain of +98% on today's $9.39. Buyers look set to stay in control over this stretch.
In 2033, RNAC is projected to trade between $10.49 and $34.85, averaging $18.68 — a potential gain of +99% from today's $9.39. That is up +1% on the projected 2032 average. Momentum favours further upside here.
Cartesian Therapeutics, Inc.'s 2034 outlook centres on $18.46, within a $9.99 to $35.29 range. That is -1% versus the projected 2033 average. That marks a +97% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, RNAC could reach as high as $35.53, with a base case around $18.18 and support toward $9.50 — roughly +94% from $9.39. Momentum favours further upside here.
Expect RNAC to range from $15.16 to $72.14 through 2040. The $33.68 average target implies a +259% move from current prices. That is up +85% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The RNAC price prediction for 2050 points to an average of $45.40 (low $20.43, high $104.42) — a potential gain of +384% on today's $9.39. Momentum favours further upside here.
Investing $1,000 in RNAC today (≈ 106.55301 RNAC) could be worth
$4,837.52
+$3,837.52 (+384%) by 2050 · US Dollar
Based on the average projected RNAC price of $45.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNACwould be worth at today's price.
$1,000 invested in RNAC on Jul 10, 2025 (≈ 73.855244 RNAC) would be worth
$693.13
-$306.87 (-30.7%) today · 0.69× · US Dollar
Based on a RNAC entry price of $13.54 vs. today's $9.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.59 | $886.21 | -11.4% |
| 1 month ago | $7.43 | $1,263.12 | +26.3% |
| 3 months ago | $5.98 | $1,569.4 | +56.9% |
| 6 months ago | $7.27 | $1,290.92 | +29.1% |
| 1 year ago | $13.54 | $693.13 | -30.7% |
| All time (5.0y) ago | $115.5 | $81.26 | -91.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNAC forecast.
Our base-case forecast reaches $19.00 around 2040.
Implied market cap at $19.00: $558.25M
The multi-year forecast paints a bullish trajectory beyond 2029. In 2030 the average price is forecast to be $13.83 with a min of $8.63 and a max of $23.80, yielding a 43% ROI and a bullish sentiment. By 2040 the average climbs to $35.79 with a max of $77.64 and a 270.1% ROI, maintaining bullish sentiment.
In 2050 the average is projected at $47.92 with a max of $110.21 and a 395.5% ROI, still bullish.
Tap a question to reveal the answer.
2030 forecast: avg $13.83, min $8.63, max $23.80, ROI 43, sentiment BULLISH.
Forecasts show neutral sentiment in the near term (e.g., 2026–2029) with gradual upside starting in 2030; ROI rises from 43% by 2030 to 270.1% by 2040 and 395.5% by 2050, but these are estimates and not guaranteed.
Yes. The forecast max values include 2040 at $77.64 and 2050 at $110.21, so reaching a price above $50 is within the forecast range, though not guaranteed.
Current price is $9.67 and market cap is $284.12M.
RSI14 is 50 with a bullish sentiment; SMA50 is $8.07 and SMA200 is $7.71. The 30-day range is $6.86 to $13.63, with support at $5.84 and resistance at $10.59.
Cartesian Therapeutics, Inc. Community Discussion
0Share your Cartesian Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.